Obesity
Conditions
Keywords
One-anastomosis gastric bypass, Duodenal-jejunal bypass with sleeve gastrectomy, Major adverse cardiovascular events, Type 2 diabetes mellitus, Obesity, Comorbidities
Brief summary
Metabolic bariatric surgery (MBS) has demonstrated its efficacy in achieving sustainable weight loss and alleviating associated comorbidities. The primary objective of our investigation is to assess the long-term impact and sustainability of weight loss, the remission of T2D as well as risk prediction of cardiovascular events following MBS concerning one-anastomosis gastric bypass (OAGB) and duodenojejunal bypass with sleeve gastrectomy (DJB-SG).
Detailed description
Metabolic bariatric surgery (MBS) offers enduring weight reduction and alleviation of obesity-related comorbidities, including dyslipidemia, type 2 diabetes (T2D), hypertension (HTN), and major adverse cardiovascular events (MACE). Long-term data on one anastomosis gastric bypass (OAGB) and duodenal-jejunal bypass with sleeve gastrectomy (DJB-SG) is lacking, necessitating this investigation. In this multicenter prospectively-collected retrospective observational study, patients with complete follow-up data at various intervals up to 3 years after surgery were included in the final analysis. The study's primary focus was to evaluate the long-term safety, efficacy, and durability of OAGB and DJB-SG in promoting weight loss and T2D remission. Additionally, changes in 10-year and lifetime risks of MACE before and 3-year after surgery were assessed using the Taiwan MACE risk prediction model and the China-PAR project model based on Taiwan national electronic health records and a large Chinese participant dataset, respectively. Hypothesis: This study contributes to providing valuable information in terms of the impacts of OAGB and DJB-SG on patients with obesity and associated diseases.
Interventions
PROCEDUREOAGB
using OAGB procedure as metabolic bariatric surgery
PROCEDUREDJB-SG
using DJB-SG procedure as metabolic bariatric surgery
Sponsors
National Defense Medical Center, Taiwan
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients whose BMI≧37.5 kg/m2 or patients whose BMI≧32.5 kg/m2 and have concurrent high-risk comorbidities, such as hypertension, obstructive sleep apnea, HbA1c≧7.5% after anti-diabetic medication treatment, etc; * The patients have been treated with lifestyle intervention, including increase in physical activity and change in diet, for more than 6 months; * Age between 20 and 65 years old; * Patients without other endocrinological causes that result in morbid obesity; * Patients without substance use, alcohol use and other psychiatric disorders; * The integrity of the patient's mental status is approved by the psychiatrist.
Exclusion criteria
* Patients who did not complete 3-year follow-up * Patients who are not eligible for surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body Mass Index (BMI) | 3 years | Weight reduction |
| Diabetes | 3 years | HbA1c change |
| Hypertension | 3 years | Blood pressure (SBP/BP change) |
| Dyslipidemia | 3 years | TG, T-CHO, LDL, HDL change |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Taiwan MACE risk prediction model | 10 years | A 10-year MACE risk prediction model developed with Taiwan national data and death registry. |
| The China-PAR project model | 10 years | A 10-year and lifetime prediction model for atherosclerotic cardiovascular disease risk in Chinese population, developed within the context of the Chinese population on a national scale. |
Outcome results
None listed